VIRP Virbac SA

377.30USD344.00 EUR · EPA-1.43%Mkt Cap: 3.16B USDP/E: 18.36

Virbac SA manufactures and sells a range of products and services for companion and farm animals in Europe, North America, Latin America, East Asia, India, Africa, the Middle East, the United States, Brazil, and the Paci…

Institutional holders10 on file

Key Statistics

Company
Market Cap3.16B USD
Enterprise Value3.37B USD
Revenue (TTM)1.64B USD
Gross Profit1.07B USD
Net Income (TTM)165.49M USD
Revenue/Share195.62 USD
Last Price377.30 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees6.4K
CountryFR
SectorHealthcare
IndustryDrug Manufacturers - General
ISINFR0000031577
Valuation
P/E (Trailing)18.36
P/E (Forward)14.69
PEG3.27
EV/EBITDA10.52
EV/Revenue2.06
P/S1.93
P/B2.37
EPS (TTM)20.55 USD
EPS (Forward)25.69 USD
52W Range
325.7551% of range427.20
52W High427.20 USD
52W Low325.75 USD
Profitability
Gross Margin66.58%
Oper. Margin15.85%
EBITDA Margin19.53%
Profit Margin10.30%
ROE13.41%
ROA7.88%
ROIC12.31%
ROCE16.46%
Growth
Revenue Growth4.00%
Earnings Growth5.90%
Cash Flow & Leverage
Operating CF218.25M USD
CapEx (TTM)112.03M USD
FCF Margin9.30%
FCF Yield4.82%
Net Debt207.22M USD
Net Debt/EBITDA0.65
Net Debt/FCF1.36
Balance Sheet
Debt/Equity0.26
Current Ratio1.77
Quick Ratio0.93
Book Value/Sh159.27 USD
Cash/Share22.58 USD
Dividends
Fwd Div Rate1.59 USD
Trail. Div Rate1.59 USD
Div. Yield0.41%
5Y Avg Yield0.37%
Payout Ratio7.80%
Ex-Div DateJul 2, 2026
Pay Date—
Splits
Last Split4:1
Split DateJul 30, 2002
Analyst Consensus
Rating—
Target (Mean)452.19 USD
Upside (mean)+19.9%
Target Range394.85 USD – 482.59 USD
394.85+19.9% to mean482.59
# Analysts7
Ownership
Shares Out.8.38M
Float4.13M
Insiders50.82%
Institutions25.81%
Technical
SMA 50363.28 (+3.9%)
SMA 200375.38 (+0.5%)
Beta0.75
S&P 52W Chg12.00%
Avg Vol (30d)4.77K
Avg Vol (10d)4.89K
Technical Indicators
RSI (14)45.4
MACD4.6488
MACD Signal7.1112
MACD Hist.-2.4624
BB Upper398.84 USD
BB Middle387.17 USD
BB Lower375.50 USD
BB Width6.03%
ATR (14)7.667 USD
Vol Ratio (20d)0.99x

About Virbac (EPA: VIRP)

›

Virbac (EPA: VIRP) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Drug Manufacturers - General industry, part of the Healthcare sector, and reports about 6,442 employees.

The shares were at 344.00 EUR on 19 November 2026, down 3.5% over 52 weeks. Its 52-week range is 297.00 EUR to 389.50 EUR: the price is 11.7% below the high and 15.8% above the low.

At a market capitalisation of 2.88B EUR, it trades at 18.4 times trailing earnings and 14.7 times forward earnings. The median trailing P/E of its 19 largest Drug Manufacturers - General peers is 26.0, a discount of 30% for VIRP. It pays a dividend yielding 0.41% (it pays out 8% of its earnings), against a median of 2.43% among the dividend payers in that peer group.

Virbac reports return on equity of 13.4%, an operating margin of 15.8% and revenue up 4.0% year over year.

Its debt exceeds its cash by 188.93M EUR, a debt-to-equity ratio of 0.26. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 7 analysts cover the stock; their mean price target of 412.29 EUR is 19.9% above the current price. The next earnings report is expected on 19 March 2027.